NeurAxis develops the IB-Stim device, a non-invasive neuromodulation therapy that targets functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8-21. This FDA-cleared solution offers a drug-free alternative to manage chronic pain without serious side effects, improving patient outcomes in the pediatric population suffering from disorders of gut-brain interactions.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FIFounders
Product
Problem
Functional abdominal pain associated with irritable bowel syndrome (IBS) and functional dyspepsia can significantly impact the quality of life for adolescents. Current treatments often involve medications with potential side effects, creating a need for drug-free alternatives.
Solution
NeurAxis offers the IB-Stim, a non-surgical, drug-free neuromodulation device cleared by the FDA for treating functional abdominal pain associated with IBS and functional dyspepsia in adolescents aged 8-21. The device delivers percutaneous electrical nerve field stimulation (PENFS) by gently stimulating cranial nerve branches on the ear. This stimulation modulates brain activity, specifically targeting areas involved in pain processing, to reduce functional abdominal pain and associated nausea. IB-Stim provides a targeted therapy that aims to improve patient outcomes without the serious side effects associated with pharmaceutical interventions.
Target Audience
The primary target audience includes pediatric gastroenterologists, pain specialists, and other healthcare providers treating adolescents suffering from functional abdominal pain associated with IBS and functional dyspepsia.
Features
- Percutaneous Electrical Nerve Field Stimulation (PENFS) delivered via a small device placed behind the ear
- Drug-free and non-surgical treatment option for functional abdominal pain
- FDA-cleared for adolescents aged 8-21 with IBS and functional dyspepsia
- Designed to modulate the gut-brain axis and reduce abnormal pain processing in the brain
- New FDA 510(k) clearance expands addressable market to include treatment of functional dyspepsia and associated nausea symptoms